Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers

Mak, Lung‐Yi; Hui, Rex Wan‐Hin; Cheung, Ka‐Shing; Seto, Wai‐Kay; Yuen, Man‐Fung

doi:10.1080/17460441.2023.2192920

Cited by 1 publication

(2 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, all pregnant women who come to the health center for childbirth guidance are tested for HBsAg and those who are positive are selected. Their serum HBV DNA is quantified and those who are above the standard value are selected and given medication [ 70 ].…”

Section: Clinical Application Of the Hbcrag Assay In Resource-limited...mentioning

confidence: 99%

“…Then, an alternative indicator to HBV DNA quantification is needed. If HBV DNA quantification is not available, it has been shown to be effective to target those who are positive by HBeAg measurement (sensitivity equivalent to enzyme-linked immunosorbent assay [ELISA]) [ 70 ]. Based on these circumstances, a rapid and easy HBcrAg assay would be useful in regions with limited resources.…”

Section: Clinical Application Of the Hbcrag Assay In Resource-limited...mentioning

confidence: 99%

See 1 more Smart Citation

Two Concepts of Hepatitis B Core-Related Antigen Assay: A Highly Sensitive and Rapid Assay or an Effective Tool for Widespread Screening

Inoue,

Yagi,

Tanaka

2024

Viruses

View full text Add to dashboard Cite

Hepatitis B core-related antigen (HBcrAg) reflects the activity of intrahepatic covalently closed circular DNA. HBcrAg can be detected even in chronic hepatitis B patients in whom serum HBV DNA or hepatitis B surface antigen is undetectable. The HBcrAg measurement system was developed based on two concepts. One is a fully-automated and highly-sensitive HBcrAg assay (iTACT-HBcrAg) and the other is a point-of-care testing (POCT) that can be used in in resource-limited areas. iTACT-HBcrAg is an alternative to HBV DNA for monitoring HBV reactivation and predicting the development of hepatocellular carcinoma. This validated biomarker is available in routine clinical practice in Japan. Currently, international guidelines for the prevention of mother-to-child transmission recommend anti-HBV prophylaxis for pregnant women with high viral loads. However, over 95% of HBV-infected individuals live in countries where HBV DNA quantification is widely unavailable. Given this situation, a rapid and simple HBcrAg assay for POCT would be highly effective. Long-term anti-HBV therapy may have potential side effects and appropriate treatment should be provided to eligible patients. Therefore, a simple method of determining the indication for anti-HBV treatment would be ideal. This review provides up-to-date information regarding the clinical value of HBcrAg in HBV management, based on iTACT-HBcrAg or POCT.

show abstract

Section: Clinical Application Of the Hbcrag Assay In Resource-limited...mentioning

confidence: 99%

Section: Clinical Application Of the Hbcrag Assay In Resource-limited...mentioning

confidence: 99%

Two Concepts of Hepatitis B Core-Related Antigen Assay: A Highly Sensitive and Rapid Assay or an Effective Tool for Widespread Screening

Inoue,

Yagi,

Tanaka

2024

Viruses

View full text Add to dashboard Cite

show abstract

Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers

Cited by 1 publication

References 132 publications

Two Concepts of Hepatitis B Core-Related Antigen Assay: A Highly Sensitive and Rapid Assay or an Effective Tool for Widespread Screening

Two Concepts of Hepatitis B Core-Related Antigen Assay: A Highly Sensitive and Rapid Assay or an Effective Tool for Widespread Screening

Contact Info

Product

Resources

About